Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
6.83
-0.24 (-3.39%)
At close: Mar 5, 2026, 4:00 PM EST
6.71
-0.12 (-1.76%)
Pre-market: Mar 6, 2026, 8:45 AM EST
Unicycive Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Unicycive Therapeutics stock have an average target of 44.5, with a low estimate of 21 and a high estimate of 75. The average target predicts an increase of 551.54% from the current stock price of 6.83.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 29, 2025.
Analyst Ratings
The average analyst rating for Unicycive Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $22 | Strong Buy | Maintains | $9 → $22 | +222.11% | Oct 29, 2025 |
| Benchmark | Benchmark | Buy Maintains $3 → $21 | Buy | Maintains | $3 → $21 | +207.47% | Sep 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $90 | Strong Buy | Initiates | $90 | +1,217.72% | May 27, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $60 | Strong Buy | Initiates | $60 | +778.48% | Apr 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +998.10% | Apr 11, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
88.74M
EPS This Year
-1.84
from -5.65
EPS Next Year
-1.35
from -1.84
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 241.2M | ||||
| Avg | n/a | 88.7M | ||||
| Low | n/a | 8.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.59 | -0.99 | ||||
| Avg | -1.84 | -1.35 | ||||
| Low | -2.18 | -1.72 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.